Antiphospholipid syndrome secondary prevention: Difference between revisions
Feham Tariq (talk | contribs) |
Feham Tariq (talk | contribs) |
||
| Line 13: | Line 13: | ||
===Reduction of reversible risk factors=== | ===Reduction of reversible risk factors=== | ||
During the perioperative period, this may include minimizing the period when patients are off anticoagulation, initiating early ambulation, and other measures to reduce venous stasis. | |||
Revision as of 20:19, 4 April 2018
|
Antiphospholipid syndrome Microchapters |
|
Differentiating Antiphospholipid syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Antiphospholipid syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Antiphospholipid syndrome secondary prevention |
|
Risk calculators and risk factors for Antiphospholipid syndrome secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Feham Tariq, MD [2]
Overview
Secondary Prevention
Long term anticoagulation
Anticoagulation for venous thrombosis:
Anticoagulation for arterial thrombosis:
Reduction of reversible risk factors
During the perioperative period, this may include minimizing the period when patients are off anticoagulation, initiating early ambulation, and other measures to reduce venous stasis.
Randomized controlled trials have addressed the secondary prevention of thromboses. These trials showed:
A systematic review has summarized the research.[3]
References
- ↑ Crowther MA, Ginsberg JS, Julian J, Denburg J, Hirsh J, Douketis J; et al. (2003). "A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome". N Engl J Med. 349 (12): 1133–8. doi:10.1056/NEJMoa035241. PMID 13679527. Review in: ACP J Club. 2004 Mar-Apr;140(2):38
- ↑ Finazzi G, Marchioli R, Brancaccio V, Schinco P, Wisloff F, Musial J; et al. (2005). "A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS)". J Thromb Haemost. 3 (5): 848–53. doi:10.1111/j.1538-7836.2005.01340.x. PMID 15869575.
- ↑ Ruiz-Irastorza G, Hunt BJ, Khamashta MA (2007). "A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies". Arthritis Rheum. 57 (8): 1487–95. doi:10.1002/art.23109. PMID 18050167.